FDA staff question Novartis cystic fibrosis drug

WASHINGTON (Reuters) - U.S. drug reviewers questioned whether Novartis AG's inhaled antibiotic treatment truly helped cystic fibrosis patients breathe better, according to documents posted online on Friday.

via Reuters: Health News Read More Here..